

Resource Summary Report

Generated by [kravitz2](#) on Sep 18, 2026

Varian Medical Systems, Inc.

RRID:SCR_017372

Type: Tool

Proper Citation

Varian Medical Systems, Inc. (RRID:SCR_017372)

Resource Information

URL: <https://www.varian.com/>

Proper Citation: Varian Medical Systems, Inc. (RRID:SCR_017372)

Description: Manufacturer located in Palo Alto, California, USA, that has made developments in fields of radiotherapy, radiosurgery, X-ray tube technology, digital image detectors, cargo screening, and non-destructive testing. Varian technology and software for processing diagnostic X-ray images is being used in radiotherapy and analysis.

Synonyms: Varian

Resource Type: commercial organization

Keywords: Manufacturer, commercial, company, component, radiotherapy, spectrometry, software, analysis, therapy, medical, imaging, technology, development

Resource Name: Varian Medical Systems, Inc.

Resource ID: SCR_017372

Alternate IDs: grid.482350.8, ISNI: 0000 0004 0482 3442, Wikidata: Q30343843

Alternate URLs: <https://ror.org/049tb1q96>

Record Creation Time: 20220129T080335+0000

Record Last Update: 20260912T195852+0000

Ratings and Alerts

No rating or validation information has been found for Varian Medical Systems, Inc..

No alerts have been found for Varian Medical Systems, Inc..

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Lacombe J, et al. (2026) A human 3D culture-organ-on-chip platform for investigating the tumor microenvironment response to ionizing radiation. *iScience*, 29(1), 114236.

Monteiro AC, et al. (2026) OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. *Cancer research communications*, 6(1), 85.

Polce SA, et al. (2026) Leveraging CT-based online adaptive radiotherapy for dose escalation in hypofractionated radiotherapy for locally advanced unresectable lung cancer. *Frontiers in oncology*, 16, 1777077.

Lin CY, et al. (2025) Personalized intensity modulation radiation therapy auto-planning for esophageal cancer. *Scientific reports*, 16(1), 2749.

Dong B, et al. (2025) Key technologies and challenges in online adaptive radiotherapy for lung cancer. *Chinese medical journal*, 138(13), 1559.

Zeng F, et al. (2024) CT-based peritumoral radiomics nomogram on prediction of response and survival to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. *Journal of cancer research and clinical oncology*, 150(2), 50.

Moore-Palhares D, et al. (2024) Radiation enhancement using focussed ultrasound-stimulated microbubbles for breast cancer: A Phase 1 clinical trial. *PLoS medicine*, 21(5), e1004408.

Gedeon A, et al. (2024) Molecular mechanism of a triazole-containing inhibitor of *Mycobacterium tuberculosis* DNA gyrase. *iScience*, 27(10), 110967.

Gill A, et al. (2024) Stereotactic body radiotherapy for early-stage lung cancer: a systematic review on the choice of photon energy and linac flattened/unflattened beams. *Radiation oncology (London, England)*, 19(1), 1.

Foote RL, et al. (2024) Mean Oral Cavity Organ-at-Risk Dose Predicts Opioid Use and Hospitalization during Radiotherapy for Patients with Head and Neck Tumors. *Cancers*, 16(2).

Hamed RA, et al. (2022) Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). *Molecular and clinical oncology*, 16(2), 40.

Saygin C, et al. (2021) Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. *Leukemia*, 35(12), 3406.

Li X, et al. (2009) A fluorescent probe for diacetyl detection. *Journal of fluorescence*, 19(4), 601.